Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities - PubMed (original) (raw)
Review
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities
Stephen B Hanauer. Inflamm Bowel Dis. 2006 Jan.
Abstract
Ulcerative colitis (UC) and Crohn's disease (CD), the primary constituents of inflammatory bowel disease (IBD), are precipitated by a complex interaction of environmental, genetic, and immunoregulatory factors. Higher rates of IBD are seen in northern, industrialized countries, with greater prevalence among Caucasians and Ashkenazic Jews. Racial gaps are closing, indicating that environmental factors may play a role. IBD is multigenic, with the most clearly established genetic link between certain NOD2 variants and CD. Regardless of the underlying genetic predisposition, a growing body of data implicates a dysfunctional mucosal immune response to commensal bacteria in the pathogenesis of IBD, especially CD. Possible triggers include a chronic inflammatory response precipitated by infection with a particular pathogen or virus or a defective mucosal barrier. The characteristic inflammatory response begins with an infiltration of neutrophils and macrophages, which then release chemokines and cytokines. These in turn exacerbate the dysfunctional immune response and activate either TH1 or TH2 cells in the gut mucosa, respectively associated with CD and, less conclusively, with UC. Elucidation of immunological and genetic factors indicate multiple points at which the inflammatory cascade may be interrupted, yielding the possibility of precise, targeted therapies for IBD.
Similar articles
- News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010.
Latella G, Fiocchi C, Caprili R. Latella G, et al. J Crohns Colitis. 2010 Dec;4(6):690-702. doi: 10.1016/j.crohns.2010.08.002. Epub 2010 Oct 8. J Crohns Colitis. 2010. PMID: 21122584 - Recent understanding of IBD pathogenesis: implications for future therapies.
Kucharzik T, Maaser C, Lügering A, Kagnoff M, Mayer L, Targan S, Domschke W. Kucharzik T, et al. Inflamm Bowel Dis. 2006 Nov;12(11):1068-83. doi: 10.1097/01.mib.0000235827.21778.d5. Inflamm Bowel Dis. 2006. PMID: 17075348 Review. - Biologic therapy for inflammatory bowel disease.
Ardizzone S, Bianchi Porro G. Ardizzone S, et al. Drugs. 2005;65(16):2253-86. doi: 10.2165/00003495-200565160-00002. Drugs. 2005. PMID: 16266194 Review. - Etiology and pathogenesis of inflammatory bowel disease.
Schmidt C, Stallmach A. Schmidt C, et al. Minerva Gastroenterol Dietol. 2005 Jun;51(2):127-45. Minerva Gastroenterol Dietol. 2005. PMID: 15990703 Review. - Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease.
Basso PJ, Fonseca MT, Bonfá G, Alves VB, Sales-Campos H, Nardini V, Cardoso CR. Basso PJ, et al. Braz J Med Biol Res. 2014 Sep;47(9):727-37. doi: 10.1590/1414-431x20143932. Epub 2014 Jul 25. Braz J Med Biol Res. 2014. PMID: 25075576 Free PMC article. Review.
Cited by
- Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals.
Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, Panaccione R, Kaplan GG, Vogel HJ, Storr M. Schicho R, et al. J Proteome Res. 2012 Jun 1;11(6):3344-57. doi: 10.1021/pr300139q. Epub 2012 May 17. J Proteome Res. 2012. PMID: 22574726 Free PMC article. - Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.
Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR; Canadian Drug Safety and Effectiveness Research Network. Alhusayen RO, et al. J Invest Dermatol. 2013 Apr;133(4):907-12. doi: 10.1038/jid.2012.387. Epub 2012 Oct 25. J Invest Dermatol. 2013. PMID: 23096714 Free PMC article. - Serological markers of inflammatory bowel disease.
Kuna AT. Kuna AT. Biochem Med (Zagreb). 2013;23(1):28-42. doi: 10.11613/bm.2013.006. Biochem Med (Zagreb). 2013. PMID: 23457764 Free PMC article. Review. - Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study.
Jiang XL, Wang HH, Cui HF. Jiang XL, et al. Med Sci Monit. 2015 Jan 13;21:163-70. doi: 10.12659/MSM.891400. Med Sci Monit. 2015. PMID: 25582578 Free PMC article. Clinical Trial. - The Anti-Inflammatory Effect of Pistacia Lentiscus in a Rat Model of Colitis.
Ostovan M, Fazljou SMB, Khazraei H, Araj Khodaei M, Torbati M. Ostovan M, et al. J Inflamm Res. 2020 Jul 22;13:369-376. doi: 10.2147/JIR.S259035. eCollection 2020. J Inflamm Res. 2020. PMID: 32801830 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources